Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparinoid topical cream, specifically containing mucopolysaccharide polysulfate (MPS), is a semi-synthetic small molecule preparation derived from mammalian cartilage. It possesses anti-coagulant, fibrinolytic, and anti-inflammatory properties. The mechanism of action involves the inhibition of enzymes such as hyaluronidase, which helps reduce tissue swelling, and the promotion of fibrinolysis to accelerate the breakdown of blood clots and bruises. This specific formulation was evaluated by Necmettin Erbakan University in a randomized controlled trial (NCT04119297) to determine its efficacy in treating periorbital edema and ecchymosis in patients following anterior craniotomy. The study found that the heparinoid cream did not significantly reduce these postoperative complications compared to cold application or routine care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparinoid topical cream.